The Duke Funding Alert newsletter, published every Monday, provides information on all new and updated grants and fellowships added to the database during the prior week. This listserv is restricted to members of the Duke community.
Congressionally Directed Medical Research Programs (CDMRP) -- Peer Reviewed Cancer Research Program (PRCRP) -- Translational Science Award
The FY20 PCRP Translational Science Award (TSA) mechanism supports advanced translational research that will foster transformation of promising ideas in prostate cancer into clinical applications, ultimately providing a solution to one or more of the FY20 PCRP Overarching Challenges. Translational research may be defined as an integration of basic science and clinical observations. Observations that drive a research idea may originate from a laboratory discovery, population-based studies, or a clinician’s firsthand knowledge of patient care. Principal Investigators (PIs) should not view translational research as a one-way continuum from bench to bedside, but can include a reciprocal flow of ideas and information between basic science and clinical science. This mechanism is intended to fund a broad range of translational studies including, but not limited to, the following:
• Advanced preclinical studies aimed at translating results from animal studies to applications with human samples/cohorts. The TSA is not intended to support initial mechanistic studies of a new target.
• Late-stage preclinical work leading to/preparing for a clinical trial, e.g., an Investigational New Drug (IND) application submission
• Correlative studies that are associated with an open/ongoing or completed clinical trial
• Projects that develop endpoints for clinical trials
• Required Pre-Application Deadline: June 25, 2020
• Application Submission Deadline: July 16, 2020
Areas of Interest
The mission of the FY20 PCRP is to fund research that will lead to the elimination of death from prostate cancer and enhance the well-being of Service members, Veterans, and all the men and their families who are experiencing the impact of the disease. Within this context, the PCRP is interested in supporting research that addresses specific gaps in prostate cancer research and clinical care, with an emphasis on investing in research that will benefit patients diagnosed with lethal prostate cancer or improve quality of life for men diagnosed with this disease. Therefore, applications are required to address one or more of the following FY20 PCRP Overarching Challenges:
• Improve the quality of life for survivors of prostate cancer
• Develop treatments that improve outcomes for men with lethal prostate cancer
• Reduce lethal prostate cancer in people of African descent, Veterans, and high-risk and underserved populations
• Define the biology of lethal prostate cancer to reduce death
Each investigator may be named on only one FY20 PCRP Translational Science Award application as PI, Initiating PI, or Partnering PI. Independent investigators at all levels are eligible to be named as PI, Initiating PI, or Partnering PI on an application for the FY20 PCRP Translational Science Award. An eligible PI, regardless of ethnicity, nationality, or citizenship status, must be employed by, or affiliated with, an eligible organization.
The anticipated direct costs budgeted for the entire period of performance for an FY20 PCRP Translational Science Award will not exceed $1M. Refer to Section II.D.5, Funding Restrictions, for detailed funding information.